10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform
10x Genomics reported Q1 revenue of $150.8 million, down 3% year-over-year but up 9% on an adjusted basis, and narrowed its net loss to $13.5 million from $34.4 million a year earlier. The company launched its Atera spatial whole-transcriptome platform, expects H2 2026 shipments, and ended Q1 with $539.8 million in cash and securities.
1. First Quarter Results
For Q1 ended March 31, 2026, revenue was $150.8 million, down 3% year-over-year but up 9% excluding a one-time $16.8 million license gain. Gross margin improved to 70% from 68%, operating expenses fell 15% to $123.2 million, and net loss narrowed to $13.5 million versus $34.4 million.
2. New Product Launch and Partnership
10x Genomics launched its Atera platform for spatial whole-transcriptome analysis with single-cell sensitivity and will begin shipping in H2 2026. The company also partnered with Bioptimus on STELA, a spatial data initiative beginning with the Xenium platform and expanding to Atera.
3. Cash Position and Guidance
The company closed Q1 with $539.8 million in cash, cash equivalents and marketable securities, a $112.9 million increase from a year earlier. 10x Genomics reaffirmed full-year revenue guidance of $600 million to $625 million, implying up to 4% growth on an adjusted basis.